Endo Health price target raised to $86 from $75 at Goldman Goldman raised Endo Health's price target to $86 from $75 and updated estimates to incorporate the Boca deal closing and the divestiture of Healthtronics. Shares are Buy rated.
News For ENDP From The Last 14 Days
Check below for free stories on ENDP the last two weeks.
Endo shares remain overvalued, says Cantor Cantor Fitzgerald raised its priced target for Endo shares to $52 from $37 ahead of the company's Q2 results, but says the stock remains overvalued. The firm keeps a Sell rating on the name.